Merck & Co., Inc.

NYSE:MRK | Last Update: Jun 12, 2025
user-image

Essential Information

Market Cap
$291.86B
Latest Price
$80.32
Fair Value*
P/E Ratio
11.68
SS Score*
Div. Yield
4.03%
WACC
5.7%
P/FCF Ratio
11.84
*This is not investment advice

Financial Summary (TTM)

Fiscal Year: January - December

Revenue
Net Income
Free Cash Flow
Shares Outstanding
EPS
ROIC
Dividend Per Share
Debt/FCF

In-Depth Analysis of Merck & Co., Inc. (MRK)

Merck & Co., Inc. (MRK), listed on the NYSE, has a market capitalization of $291.86B. As of Jun 12, 2025, the stock is trading at $80.32 per share, offering investors a clear view of its current market value. Merck & Co., Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.

With a P/E ratio of 11.68, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Merck & Co., Inc. also offers a dividend yield of 4.03%, making it an attractive option for income-focused investors who seek regular dividends.

Our Discounted Cash Flow (DCF) analysis reveals that Merck & Co., Inc. (MRK) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.

The proprietary SS Score for Merck & Co., Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.

To view the detailed SS Score for Merck & Co., Inc., Login or Upgrade for access.

The Price to Free Cash Flow (P/FCF) ratio for Merck & Co., Inc. is 11.84, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.

In summary, Merck & Co., Inc. (MRK) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.

*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.

Frequently Asked Questions about Merck & Co., Inc. (MRK)

Is Merck & Co., Inc. a good stock to buy?

Whether Merck & Co., Inc. (MRK) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.

What is the fair value of Merck & Co., Inc.?

The fair value of Merck & Co., Inc. (MRK) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.

What is Merck & Co., Inc.'s SS Score?

The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Merck & Co., Inc.. To access the full SS Score, consider upgrading your subscription.

How does Merck & Co., Inc. compare to other stocks in the industry sector?

Merck & Co., Inc. is a significant player in the industry sector, with a market capitalization of $291.86B and a competitive P/E ratio of 11.68. Investors should compare these metrics with industry peers to gauge whether Merck & Co., Inc. is outperforming or underperforming within its sector.

News about Merck & Co., Inc. (MRK)

Seeking Alpha

Merck: Best Case For Option Collars We'll Ever See

I use option collars on struggling stocks like Merck & Co., Inc. to cap downside risk while maintaining upside potential, especially when the technicals look uncertain. My MRK collar trade earlier thi...

2 days agoCNBC Television

Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee

CNBC's Angelica Peebles reports on news regarding vaccines.

Reuters

US FDA approves Merck's RSV antibody for infants

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the c...

Forbes

Is Merck Stock About To Crash?

Why would you consider buying Johnson & Johnson stock (NYSE:JNJ) at 17 times its trailing earnings when Merck stock (NYSE: MRK) trades at around 13 times? After all, Merck has nearly 10% average reven...

10 days agoCNBC Television

Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz

Jared Holz, Mizuho health care equity strategist, joins 'The Exchange' to discuss the impact of tariffs on pharmaceuticals and how to trade in the sector.

Forbes

Merck Stock's Ticking Keytruda Time Bomb

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is large...

Seeking Alpha

Top 10 High-Yield Dividend Stocks

The liberation day market selloff has been entirely recovered during the month of May. Since inception, my watchlist has a CAGR of 14.81%, performing in-line with SPY and VYM, while providing a superi...

Our content is for educational use only, not investment advice. By using it, you agree to our Terms of Use.